Properties
SPID® prints tablets with separate drug compartments, programmable release and pharmacopeial quality
SPID® builds each tablet layer by layer from water-based pastes, without high temperature or compression. Published studies show immediate, extended, sequential and pH-dependent release from a single tablet, with hardness, friability and mass uniformity meeting European Pharmacopoeia requirements.
Key properties
| Property | SPID® | Evidence |
|---|---|---|
| Manufacturing principle | Additive screen printing of water-based pastes, layer by layer; no high temperature or pressure | Pharmaceutics 2025 |
| Release profiles | Immediate, extended, delayed, sequential and pH-dependent, alone or combined in one tablet | Int J Pharm 2023, Pharmaceutics 2025 |
| Compartments per tablet | Two and three compartments published; designs with more compartments possibleFreigabe prüfen„beliebig viele“ bzw. vier nur intern belegt | Pharmaceutics 2025 |
| Enteric protection | Enteric polymer (HPMC-AS) printed directly into a compartment – no separate coating step | Pharmaceutics 2025 |
| Layer thickness | From 10 µm; 10–150 µm per layer | Laxxon, Adare |
| Units per print | 330 tablets per 205 × 205 mm print area on a lab-scale screen | Pharmaceutics 2024 |
| Production capacity | Up to 1.5 million units per day on production-scale equipmentFreigabe prüfengemessen oder ausgelegt? Welche Anlage? | Laxxon |
| Scale-up | Same process from R&D batches to commercial volumes | Laxxon, Adare |
| Tablet quality | Hardness, friability (0.002–0.24%) and mass uniformity (0.6–1.7%) meet European Pharmacopoeia requirements | Int J Pharm 2023, Pharmaceutics 2025 |
| Drug load | About 60% active ingredient by weight in the finished tabletFreigabe prüfenintern bis 70–75 % genannt | Pharmaceutics 2025 |
| Unit size | Published: 14 × 5 × 3.6 mm tablets; microtablets down to 0.75 mmFreigabe prüfenMikrotabletten nur intern | Pharmaceutics 2025 |
| Excipients | Standard pharmaceutical excipients, e.g. hydroxypropyl cellulose, microcrystalline cellulose, mannitol, glycerol, talc | Pharmaceutics 2025 |
| Anti-counterfeiting | Covert inner structures and QR codes printed into each tablet in the same run | Pharmaceutics 2024, BJSTR 2022 |
| Operator safety | No dust during printing, because all powders are wetted in the pasteFreigabe prüfennur interne Präsentation, keine Messdaten | – |
| Peptides | Peptide structure unchanged after printingFreigabe prüfeninterne CD-Spektren, vertraulich | – |
| Other dosage forms | Films, implants, transdermal patchesFreigabe prüfenkeine Daten veröffentlicht | Laxxon |
What this enables
Fewer daily doses. Extended and multi-phase release can replace several immediate-release doses with one tablet.
Two drugs, one tablet, the right order. Separate compartments release incompatible or complementary drugs one after another.
Targeted release in the gut. Enteric compartments release their drug only at the pH of a chosen intestinal region.
New patent protection. Each SPID® formulation is a new, patentable product – the basis for 505(b)(2) and lifecycle programs.
Constant release over time (zero-order kinetics). Freigabe prüfenKonzept nur intern, keine Daten veröffentlicht
Formulation considerations
Freigabe prüfenganzer Abschnitt aus internen Unterlagen; offen genannte Grenzen machen die Seite glaubwürdiger
- Active ingredients that react with water are not suited to the water-based paste.
- Printability depends mainly on paste rheology and particle size; Laxxon screens each candidate before development.
- Residual moisture is controlled during drying to keep layers firmly bonded.
Last updated: PlatzhalterDatumReviewed by: PlatzhalterName, Funktion